We are live on ! Find out more
NVS icon

Novartis

1,407 hedge funds and large institutions have $17.2B invested in Novartis in 2025 Q3 according to their latest regulatory filings, with 102 funds opening new positions, 475 increasing their positions, 482 reducing their positions, and 74 closing their positions.

New
Increased
Maintained
Reduced
Closed

38% more first-time investments, than exits

New positions opened: 102 | Existing positions closed: 74

1% more funds holding

Funds holding: 1,389 → 1,407 (+18)

5% more capital inflows, than outflows

Capital inflows: $1.08B | Capital outflows: $1.02B

0.16% more ownership

Funds ownership: 6.75% → 6.92% (+0.16%)

1% less repeat investments, than reductions

Existing positions increased: 475 | Existing positions reduced: 482

34% less call options, than puts

Call options by funds: $261M | Put options by funds: $398M

35% less funds holding in top 10

Funds holding in top 10: 17 → 11 (-6)

Holders
1,407
Holders Change
+18
Holders Change %
+1.3%
% of All Funds
18.37%
Holding in Top 10
11
Holding in Top 10 Change
-6
Holding in Top 10 Change %
-35.29%
% of All Funds
0.14%
New
102
Increased
475
Reduced
482
Closed
74
Calls
$261​M
Puts
$398​M
Net Calls
-⁠$136​M
Net Calls Change
-⁠$74.7​M

NVS Hedge Fund Activity: Q3 2025 in Review

1,407 of the 7,660 institutional investors tracked by Wall St. Rank reported a position in Novartis (NVS) for Q3 2025, worth a combined $17.2B — up 6.4% from $16.2B a quarter earlier.

Buyers outnumbered sellers: 102 funds opened new NVS positions and 74 closed out — a net gain of 28 holders — while 475 added to existing stakes and 482 trimmed.

The largest buyer was GQG Partners, adding an estimated $268M. The largest seller was Wellington Management Group, cutting an estimated $134M.

  • 1,407 institutional investors held Novartis (NVS) as of Q3 2025, up from 1,389 in Q2 2025.
  • Funds reported $17.2B of Novartis stock for Q3 2025, up 6.4% quarter-over-quarter.
  • 102 funds opened new Novartis positions in Q3 2025 and 74 closed out, a net change of +28 holders.
  • The largest Novartis buyer in Q3 2025 was GQG Partners, an estimated $268M added.
  • The largest Novartis seller in Q3 2025 was Wellington Management Group, an estimated $134M sold.

Based on aggregated 13F filings for Q3 2025.